Association between Tpeak-Tend interval and QT prolongation: a study of sertindole and sotalol

Research output: Contribution to journalReviewResearchpeer-review

Standard

Association between Tpeak-Tend interval and QT prolongation : a study of sertindole and sotalol. / Shakibfar, Saeed; Struijk, Johannes J.; Kanters, Jørgen K.; Nielsen, Jimmi; Schmidt, Samuel; Graff, Claus.

In: Pharmacology, Drug Development & Therapeutics, Vol. 1, No. 2, 2017, p. 1-6.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Shakibfar, S, Struijk, JJ, Kanters, JK, Nielsen, J, Schmidt, S & Graff, C 2017, 'Association between Tpeak-Tend interval and QT prolongation: a study of sertindole and sotalol', Pharmacology, Drug Development & Therapeutics, vol. 1, no. 2, pp. 1-6. https://doi.org/10.15761/PDDT.1000106

APA

Shakibfar, S., Struijk, J. J., Kanters, J. K., Nielsen, J., Schmidt, S., & Graff, C. (2017). Association between Tpeak-Tend interval and QT prolongation: a study of sertindole and sotalol. Pharmacology, Drug Development & Therapeutics, 1(2), 1-6. https://doi.org/10.15761/PDDT.1000106

Vancouver

Shakibfar S, Struijk JJ, Kanters JK, Nielsen J, Schmidt S, Graff C. Association between Tpeak-Tend interval and QT prolongation: a study of sertindole and sotalol. Pharmacology, Drug Development & Therapeutics. 2017;1(2):1-6. https://doi.org/10.15761/PDDT.1000106

Author

Shakibfar, Saeed ; Struijk, Johannes J. ; Kanters, Jørgen K. ; Nielsen, Jimmi ; Schmidt, Samuel ; Graff, Claus. / Association between Tpeak-Tend interval and QT prolongation : a study of sertindole and sotalol. In: Pharmacology, Drug Development & Therapeutics. 2017 ; Vol. 1, No. 2. pp. 1-6.

Bibtex

@article{99d09a642e414b75868c39e693c6c5d3,
title = "Association between Tpeak-Tend interval and QT prolongation: a study of sertindole and sotalol",
abstract = "The electrocardiographic interval between the peak and the end of the T-wave (Tpe) is believed to be an arrhythmic risk marker. However, there are also a number of reports that are inconsistent with the usefulness of Tpe for identifying abnormal repolarization. This study was designed to investigate how the Tpe prolongation is correlated to a prolonged QT interval, induced by IKr-blockers. The study included two data sets. A first group of 21 healthy subjects received 160 mg and 320 mg doses of d,l-sotalol. The second group, of 40 patients with schizophrenia, was switched to 16 mg sertindole treatment. The Fridericia corrected QT prolongations (QTcF) and the mean Tpe changes (∆Tpe) were: d,l-sotalol 160 mg: ∆QTcF=29 ms & ∆Tpe=4.7 ms, 320 mg: ∆QTcF=51 ms & ∆Tpe=6.2 ms, sertindole 16 mg: ∆QTcF=17 ms & ∆Tpe=8.5 ms. There were low correlations (r) between ∆QTcF and ∆Tpe in both d,l-sotalol groups and sertindole group. Given the lack of linear relationship between Tpe and QT in response to potential torsadogenic drugs, this study raises doubt about the usefulness of Tpe as a biomarker for repolarization changes and torsadogenic potential in drug safety studies.",
author = "Saeed Shakibfar and Struijk, {Johannes J.} and Kanters, {J{\o}rgen K.} and Jimmi Nielsen and Samuel Schmidt and Claus Graff",
year = "2017",
doi = "10.15761/PDDT.1000106",
language = "English",
volume = "1",
pages = "1--6",
journal = "Pharmacology, Drug Development & Therapeutics",
issn = "2399-7389",
number = "2",

}

RIS

TY - JOUR

T1 - Association between Tpeak-Tend interval and QT prolongation

T2 - a study of sertindole and sotalol

AU - Shakibfar, Saeed

AU - Struijk, Johannes J.

AU - Kanters, Jørgen K.

AU - Nielsen, Jimmi

AU - Schmidt, Samuel

AU - Graff, Claus

PY - 2017

Y1 - 2017

N2 - The electrocardiographic interval between the peak and the end of the T-wave (Tpe) is believed to be an arrhythmic risk marker. However, there are also a number of reports that are inconsistent with the usefulness of Tpe for identifying abnormal repolarization. This study was designed to investigate how the Tpe prolongation is correlated to a prolonged QT interval, induced by IKr-blockers. The study included two data sets. A first group of 21 healthy subjects received 160 mg and 320 mg doses of d,l-sotalol. The second group, of 40 patients with schizophrenia, was switched to 16 mg sertindole treatment. The Fridericia corrected QT prolongations (QTcF) and the mean Tpe changes (∆Tpe) were: d,l-sotalol 160 mg: ∆QTcF=29 ms & ∆Tpe=4.7 ms, 320 mg: ∆QTcF=51 ms & ∆Tpe=6.2 ms, sertindole 16 mg: ∆QTcF=17 ms & ∆Tpe=8.5 ms. There were low correlations (r) between ∆QTcF and ∆Tpe in both d,l-sotalol groups and sertindole group. Given the lack of linear relationship between Tpe and QT in response to potential torsadogenic drugs, this study raises doubt about the usefulness of Tpe as a biomarker for repolarization changes and torsadogenic potential in drug safety studies.

AB - The electrocardiographic interval between the peak and the end of the T-wave (Tpe) is believed to be an arrhythmic risk marker. However, there are also a number of reports that are inconsistent with the usefulness of Tpe for identifying abnormal repolarization. This study was designed to investigate how the Tpe prolongation is correlated to a prolonged QT interval, induced by IKr-blockers. The study included two data sets. A first group of 21 healthy subjects received 160 mg and 320 mg doses of d,l-sotalol. The second group, of 40 patients with schizophrenia, was switched to 16 mg sertindole treatment. The Fridericia corrected QT prolongations (QTcF) and the mean Tpe changes (∆Tpe) were: d,l-sotalol 160 mg: ∆QTcF=29 ms & ∆Tpe=4.7 ms, 320 mg: ∆QTcF=51 ms & ∆Tpe=6.2 ms, sertindole 16 mg: ∆QTcF=17 ms & ∆Tpe=8.5 ms. There were low correlations (r) between ∆QTcF and ∆Tpe in both d,l-sotalol groups and sertindole group. Given the lack of linear relationship between Tpe and QT in response to potential torsadogenic drugs, this study raises doubt about the usefulness of Tpe as a biomarker for repolarization changes and torsadogenic potential in drug safety studies.

U2 - 10.15761/PDDT.1000106

DO - 10.15761/PDDT.1000106

M3 - Review

VL - 1

SP - 1

EP - 6

JO - Pharmacology, Drug Development & Therapeutics

JF - Pharmacology, Drug Development & Therapeutics

SN - 2399-7389

IS - 2

ER -

ID: 183809485